Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Esperion Expects Preferred Formulary Placement For Oral Cholesterol Drug Bempedoic Acid

Executive Summary

Final Phase III study for pivotal package of cholesterol drug bempedoic acid shows LDL-lowering efficacy and a clean safety profile, paving the way for filings in the first half of 2019.

Advertisement

Related Content

What The New US Cholesterol Treatment Guidelines Mean For Esperion
Amgen Drops Repatha List Price 60% To Cut Medicare Co-Pays And Boost Use
'That's Huge, Folks': Amarin's Vascepa Cuts CV Risk By 25% On Top Of Statins
Esperion Aims Low On Price For Cholesterol Drug Bempedoic Acid
Esperion Posts Positive Phase III Bempedoic Acid Results, But Future Fixed-Dose Data Are Key
Deaths In Esperion's Long-Term Bempedoic Acid Trial Spur Fears Of Commercial Delay

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124079

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel